Publications

Imeglimine

Mechanism of Action of Imeglimin: A Novel Therapeutic Agent for Type 2 Diabetes

Hallakou-Bozec, S., G. Vial, M. Kergoat, P. Fouqueray, S. Bolze, A.L. Borel, E. Fontaine, and D.E. Moller — 2021

Imeglimin Amplifies Glucose-stimulated Insulin Release From Diabetic Islets Via a Distinct Mechanism of Action

Hallakou-Bozec, S., M. Kergoat, P. Fouqueray, S. Bolze, and D.E. Moller — 2021

Short-and Long-term Administration of Imeglimin Counters Cardiorenal Dysfunction in a Rat Model of Metabolic Syndrome

Lachaux, M., M. Soulie, M. Hamzaoui, A. Bailly, L. Nicol, I. Remy-Jouet, S. Renet, C. Vendeville, P. Gluais-Dagorn, S. Hallakou-Bozec, C. Monteil, V. Richard, and P. Mulder — 2020

Imeglimin Preserves Islet β-cell Mass in Type 2 Diabetic ZDF Rats

Hallakou-Bozec, S., M. Kergoat, D.E. Moller, and S. Bolze — 2020

Absence of QTc Prolongation in a Thorough QT Study with Imeglimin, a First in Class Oral Agent for Type 2 Diabetes Mellitus

Dubourg, J., S. Perrimond-Dauchy, M. Felices, S. Bolze, P. Voiriot, and P. Fouqueray — 2020

Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment

Chevalier, C., J. Dubourg, S. Bolze, and P. Fouqueray — 2020

Imeglimin Lowers Glucose Primarily by Amplifying Glucose-stimulated Insulin Secretion in High-fat-fed Rodents

Perry, R.J., R.L. Cardone, M.C. Petersen, D. Zhang, P. Fouqueray, S. Hallakou-Bozec, S. Bolze, G.I. Shulman, K.F. Petersen, and R.G. Kibbey — 2016

Imeglimin Prevents Human Endothelial Cell Death by Inhibiting Mitochondrial Permeability Transition Without Inhibiting Mitochondrial Respiration

Detaille, D., G. Vial, A.L. Borel, C. Cottet-Rouselle, S. Hallakou-Bozec, S. Bolze, P. Fouqueray, and E. Fontaine — 2016

Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-fat, High-sucrose Diet Mice Model

Vial, G., M.A. Chauvin, N. Bendridi, A. Durand, E. Meugnier, A.M. Madec, N. Bernoud-Hubac, J.P. Pais de Barros, E. Fontaine, C. Acquaviva, S. Hallakou-Bozec, S. Bolze, H. Vidal, and J. Rieusset — 2015

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Sitagliptin Monotherapy

Fouqueray, P., V. Pirags, M. Diamant, G. Schernthaner, H.E. Lebovitz, S.E. Inzucchi, and C.J. Bailey — 2014

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

Fouqueray, P., V. Pirags, S.E. Inzucchi, C.J. Bailey, G. Schernthaner, M. Diamant, and H.E. Lebovitz — 2013

Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes

Fouqueray, P., X. Leverve, E. Fontaine, M. Baquié, C. Wollheim, H. Lebovitz, and S. Bozec — 2011

PXL065